In vivo and in vitro anti-hookworm effect of Single dose of Albendazole among outpatients at Adet primary Hospital, Northwest, Ethiopia
Phase 4
- Conditions
- Hookworm infections
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
? All outpatients agree to comply with study procedures, including the provision of two enough stool samples at the beginning (baseline) and at post-treatment follow up assessments (approximately 2 weeks, later).
? All hookworm positive study participants > 2 years old
? Both sex (female and male ) hookworm positive participants
Exclusion Criteria
? Pregnant women
? Patients undertake anthelminthic drugs during data collection time within the past 6 weeks)
? Participants with medication with known interaction (e.g. for albendazole: cimetidine, praziquantel, and dexamethasone)
? Patients who had a history of severe chronic disease (e.g.cancer, diabetes, chronic heart, liver or renal disease).
? Participants having diarrhea or vomiting
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cure rate and egg reduction rates of single doses of albendazole were the primary outcomes of this study
- Secondary Outcome Measures
Name Time Method MIC of albendazole killing effects for hookworm larva in culture media